drugset / Trial / NCT00375492

Effect on Weight Loss of Exenatide Versus Placebo

NCT00375492

Phase 3 Completed 196 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is designed to compare the effects of twice-daily exenatide and twice-daily placebo on weight loss. This trial will evaluate overweight and obese subjects with type 2 diabetes who have inadequate glycemic control with metformin, sulfonylurea, or metformin plus a sulfonylurea. Subjects will be treated with exenatide or placebo in addition to their current oral antidiabetes agent regimen and participate in a lifestyle modification program.

Timeline

Start
2006-09
Primary completion
2008-02
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 5 ug Subcutaneous
Subject Exenatide Peptide 10 ug Subcutaneous